Current Report Filing (8-k)
February 13 2020 - 04:49PM
Edgar (US Regulatory)
0001320414 false 0001320414 2020-02-11
2020-02-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
8-K
current
report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
February 12, 2020
SELECT MEDICAL HOLDINGS CORPORATION
(Exact name of registrant as specified in its charter)
|
Delaware |
|
001-34465 |
|
20-1764048 |
(State or other
jurisdiction of
Incorporation) |
|
(Commission
File
Number) |
|
(I.R.S. Employer
Identification No.) |
4714 Gettysburg Road,
P.O. Box 2034
Mechanicsburg,
PA
17055
(Address of principal executive offices) (Zip Code)
(717)
972-1100
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class |
Trading Symbol(s) |
Name of each exchange on which
registered |
|
Common Stock, par value $0.001 per share |
SEM |
New York Stock Exchange (NYSE) |
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
¨ |
Written communications pursuant to
Rule 425 under the Securities Act (17 CFR 230.425) |
|
¨ |
Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
¨ |
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)) |
|
¨ |
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c)) |
Indicate by check mark whether either registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
¨
If an emerging growth company, indicate by check mark if either
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act. ¨
Item 5.02 Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
On February 12, 2020, Leopold Swergold, a member of the Board of
Directors (the “Board”) of Select Medical Holdings Corporation and
Select Medical Corporation (together, the “Company”) and a member
of the Audit and Compliance Committee and the Compensation
Committee of the Board, notified the Company of his decision not to
stand for reelection as a member of the Board at the end of his
current term, which will expire at the Annual Meeting of
Stockholders of the Company to be held on April 28, 2020. Mr.
Swergold’s retirement was not the result of any disagreement with
the Company.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrants have duly caused this report to be signed on
their behalf by the undersigned, thereunto duly authorized.
| |
|
SELECT MEDICAL HOLDINGS CORPORATION |
| |
|
|
| |
|
|
| Date: February
13, 2020 |
|
By: |
/s/ Michael E. Tarvin |
| |
|
|
Michael
E. Tarvin |
| |
|
|
Executive Vice President, General Counsel and
Secretary |
Select Medical (NYSE:SEM)
Historical Stock Chart
From Dec 2020 to Jan 2021
Select Medical (NYSE:SEM)
Historical Stock Chart
From Jan 2020 to Jan 2021
